Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced <i>EGFR</i>-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced <i>EGFR</i>-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis

(1) Background: Several randomized controlled trials (RCTs) have been conducted in combination with Efficacy and Safety of Epidermal Growth Factor Receptor(EGFR)-Tyrosine Kinase Inhibitor (TKI) for the first-line treatment of patients with advanced non-small cell lung cancer; however, head-to-head c...

Full description

Bibliographic Details
Main Authors: Jianchao Xue, Bowen Li, Yadong Wang, Zhicheng Huang, Xinyu Liu, Chao Guo, Zhibo Zheng, Naixin Liang, Xiuning Le, Shanqing Li
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
EGFR-TKI
combination therapy
Bayesian network meta-analysis
non-small cell lung cancer
Online Access:https://www.mdpi.com/2072-6694/14/19/4894

Internet

https://www.mdpi.com/2072-6694/14/19/4894

Similar Items